Yom Chai is a research and product development company based in Israel and was established in 2018.The companies’ objective is to conduct pre-clinical research and clinical trials in Israel utilizing extracted components from diverse cannabis cultivars with specific cannabinoid and terpene profiles to treat patients with various diseases. The company will be focused on three main categories: (1) Gastrointestinal, (2) Neurodevelopmental and (3) Neurodegenerative. Yom Chai will be targeting people suffering from life devastating diseases which will include crohn’s disease, attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig’s Disease.
The company has established relationships with strategic international partners to produce, manufacture, distribute and retail the scientifically proven product. The company will source unique and proprietary genetics from some of the leading breeders in the world and will operate in full compliance with all the appropriate international regulatory standards for the development of cannabis-based products. Yom Chai has assembled some of the most world’s renowned cannabis scientists, formulators, plant geneticist, project managers and distribution partners from around the world with more than 20 years of experience cumulative. The companies’ scientific team has expertise in pre-clinical research and clinical trial design which gives them significant advantages and greater possibilities of having one or more successful outcomes. The companies scientific and formulating team consist of iCANN, EndoCRO, CANNRX, Steep Hill, and Kaneh-B, just to name a few. The time frame for each trial will be up to two years for completion. The data obtained while the clinical trials are being conducted will be utilized for direct formulation to create full-spectrum medical cannabis products. The company will use partial trial data to formulate and distribute products in the global cannabis marketplace where applicable and legal by law. Yom Chai’s strategy is to continue to acquire and develop cutting-edge Intellectual Property while obtaining new patients worldwide. The company plans to acquire import and export licenses in various international markets, which include, Europe, Canada, South America, and the United States. The company will acquire these licenses as each country legalizes’ the sale of cannabis and cannabis-related products.